All Stories

Pfizer-backed CellCentric secures $120M for further myeloma trials

Pfizer-backed CellCentric has secured $120 million in series C funds as the British biotech prepares to take its multiple myeloma drug into pivotal trials.

May 19, 2025 - 14:50
 0
Pfizer-backed CellCentric secures $120M for further myeloma trials
Pfizer-backed CellCentric has secured $120 million in series C funds as the British biotech prepares to take its multiple myeloma drug into pivotal trials.
Read More

Tags:

Previous Article

Regulatory tracker: GSK's Blenrep, Roche's Vabysmo win approvals in Japan

Next Article

Armata links bacteria-killing virus to clinical responses in phase 2 trial

Related Posts

RA Capital’s biotech incubator lays off staffers: Stat

RA Capital’s biotech incubator lays off staffers: Stat

May 14, 2025  0

Kinase inhibitor biotech Enliven calls time on phase 1 HER2 solid tumor program

Kinase inhibitor biotech Enliven calls time on phase 1 ...

May 15, 2025  0

Innovative Breakthrough in Cancer Testing Developed in Ohio

Innovative Breakthrough in Cancer Testing Developed in ...

May 19, 2025  0